Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 2 of 14

13. Axsome Therapeutics Inc (NASDAQ:AXSM)

Number of Hedge Fund Holders In Q4 2024: 44

Axsome Therapeutics Inc (NASDAQ:AXSM) is a biopharmaceutical company that makes treatments for CNS disorders that don’t have reliable alternative treatments.

The stock is up significantly so far in 2025 due to the settlement of patent litigation with Teva Pharmaceuticals regarding AUVELITY, their treatment for major depressive disorder. This agreement prevents Teva from launching a generic version until at least September 2038 (or March 2039 if pediatric exclusivity is granted).

Another major catalyst was the FDA approval of SYMBRAVO for the acute treatment of migraine with or without aura in adults. This was announced in early 2025.

The company also has positive Phase 3 clinical trials for two key pipeline candidates for Alzheimer’s and narcolepsy.

The consensus price target of $165.36 implies 30.81% upside.

AXSM is up 49.39% year-to-date.

Page 2 of 14